Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-driven cancers, reported its third-quarter financial results for the period ending September 30, 2024, and shared updates on corporate progress. The company’s mission centers on…
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, has announced positive results from Study 304, which evaluated the efficacy and safety of lumateperone 42 mg for preventing relapse in adults with…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced the appointment of Alan Bash as the President of CARVYKTI®. In this newly established position, Mr. Bash will oversee the ongoing growth of CARVYKTI®, managing Legend Biotech’s…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the launch of a new disease awareness campaign titled “We’ll Get There Soon” on FCS Awareness Day. The initiative aims to raise awareness about Familial Chylomicronemia Syndrome (FCS), a rare and severe condition…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted therapy for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older. The…
Eli Lilly and Company (NYSE: LLY) has announced that data from the Phase 3 EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader (SERD), will be presented for the first time in a late-breaking oral session at the San…
On the morning of October 30, Ma Xin, a member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, visited Jiangsu Hansoh, a subsidiary of Hansoh Pharma. Accompanying him were Yang Xinchong, Secretary-General of the…
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has announced encouraging new data from the Phase 3 SOLARIS trial on TEV-‘749, a subcutaneous extended-release injection for schizophrenia. In the study’s acute treatment phase (Period…
Teva Pharmaceuticals, the U.S. branch of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has released interim findings from its Phase 4 IMPACT-TD Registry study. This large-scale study sheds light on the differences in tardive dyskinesia (TD) among patients with…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) released its third-quarter 2024 financial and operational results, showcasing strong revenue growth and notable corporate developments. CEO Commentary on Performance and Growth “Our third-quarter performance highlights our strong momentum, with revenue up by 34% and…
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its financial results and business highlights for the third quarter ended September 30, 2024, along with updated financial guidance. Strong AYVAKIT Performance and Growth Outlook “With AYVAKIT’s strong revenue performance this quarter, our…
In October 2024, the World Health Organization (WHO), alongside its partners and Member States, activated the Global Health Emergency Corps (GHEC) for the first time to support countries grappling with mpox outbreaks. The GHEC is a coalition of professionals established…